AU2020307532A1 - Attenuated dengue viruses - Google Patents

Attenuated dengue viruses Download PDF

Info

Publication number
AU2020307532A1
AU2020307532A1 AU2020307532A AU2020307532A AU2020307532A1 AU 2020307532 A1 AU2020307532 A1 AU 2020307532A1 AU 2020307532 A AU2020307532 A AU 2020307532A AU 2020307532 A AU2020307532 A AU 2020307532A AU 2020307532 A1 AU2020307532 A1 AU 2020307532A1
Authority
AU
Australia
Prior art keywords
protein
recoded
vims
codon
parent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020307532A
Other languages
English (en)
Inventor
John Robert Coleman
Steffen Mueller
Charles STAUFT
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codagenix Inc
Original Assignee
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc filed Critical Codagenix Inc
Publication of AU2020307532A1 publication Critical patent/AU2020307532A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2020307532A 2019-06-25 2020-06-23 Attenuated dengue viruses Pending AU2020307532A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962866477P 2019-06-25 2019-06-25
US62/866,477 2019-06-25
PCT/US2020/039166 WO2020263850A1 (en) 2019-06-25 2020-06-23 Attenuated dengue viruses

Publications (1)

Publication Number Publication Date
AU2020307532A1 true AU2020307532A1 (en) 2022-01-27

Family

ID=74060347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020307532A Pending AU2020307532A1 (en) 2019-06-25 2020-06-23 Attenuated dengue viruses

Country Status (16)

Country Link
US (1) US20220347285A1 (https=)
EP (2) EP3990014A4 (https=)
JP (2) JP2022540773A (https=)
CN (1) CN114302738A (https=)
AU (1) AU2020307532A1 (https=)
BR (1) BR112021026201A8 (https=)
CA (1) CA3145401A1 (https=)
CL (1) CL2021003475A1 (https=)
CO (1) CO2021017772A2 (https=)
CR (1) CR20210677A (https=)
DO (1) DOP2021000271A (https=)
IL (1) IL289274A (https=)
MX (1) MX2022000038A (https=)
PE (1) PE20220296A1 (https=)
PH (1) PH12021553305A1 (https=)
WO (1) WO2020263850A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
KR101621100B1 (ko) 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US20120269849A1 (en) 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
BR112017004452B1 (pt) * 2014-09-05 2023-12-12 The Research Foundation For The State University Of New York Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
US11111481B2 (en) * 2015-09-30 2021-09-07 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved RNA structure
CA3016697A1 (en) * 2016-03-11 2017-09-14 The Johns Hopkins University Live attenuated zika virus vaccine
WO2019172982A1 (en) * 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses

Also Published As

Publication number Publication date
PH12021553305A1 (en) 2022-08-01
CL2021003475A1 (es) 2023-01-06
IL289274A (en) 2022-02-01
CR20210677A (es) 2022-04-26
MX2022000038A (es) 2022-02-24
WO2020263850A1 (en) 2020-12-30
EP3990014A1 (en) 2022-05-04
CA3145401A1 (en) 2020-12-30
BR112021026201A8 (pt) 2022-05-10
BR112021026201A2 (pt) 2022-02-15
CO2021017772A2 (es) 2022-04-19
CN114302738A (zh) 2022-04-08
JP2022540773A (ja) 2022-09-20
US20220347285A1 (en) 2022-11-03
DOP2021000271A (es) 2022-04-18
JP2025041836A (ja) 2025-03-26
PE20220296A1 (es) 2022-03-07
EP4707387A2 (en) 2026-03-11
EP3990014A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
US20250235522A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
US12168049B2 (en) Attenuated flaviviruses
Netland et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease
CN111778263B (zh) 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
Pratt et al. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models
EP2319532A1 (en) Recombinant dengue virus containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 3, or 4
WO2018090994A1 (zh) 口蹄疫病毒温度敏感减毒株及其构建方法和用途
US20220347285A1 (en) Attenuated dengue viruses
US20250057932A1 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
CN111961654B (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
US20070036827A1 (en) West nile virus vaccine
Zhang et al. Long-term passage of duck Tembusu virus in BHK-21 cells generates a completely attenuated and immunogenic population with increased genetic diversity
EP3866847A1 (en) Virus vaccine
Qi et al. A reassortment vaccine candidate as the improved formulation to induce protection against very virulent infectious bursal disease virus
RU2788130C2 (ru) Живой аттенуированный штамм вируса желтой лихорадки, адаптированный к росту в клетках vero, и вакцинная композиция, содержащая его